Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.

[1]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[2]  G. Tepe,et al.  Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial , 2015 .

[3]  S. Duda,et al.  Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first‐in‐human study , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Jae Joong Lee,et al.  Comparison of diabetic and non-diabetic patients undergoing endovascular revascularization for peripheral arterial disease. , 2015, The Journal of invasive cardiology.

[5]  J. Matsumura,et al.  A single stent strategy in patients with lifestyle limiting claudication: 3‐year results from the Durability II trial , 2015, Catheterization and Cardiovascular Interventions.

[6]  D. Scheinert,et al.  Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease , 2015, Circulation.

[7]  T. Mueller,et al.  Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. , 2014, Journal of vascular surgery.

[8]  D. Scheinert,et al.  Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the Complete SE Multicenter Trial , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[9]  D. Dawson,et al.  Nitinol Self-Expanding Stents vs. Balloon Angioplasty for Very Long Femoropopliteal Lesions , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[10]  M. Dake,et al.  Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. , 2013, Journal of the American College of Cardiology.

[11]  T. Albrecht,et al.  Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.

[12]  M. Böhm,et al.  Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel? , 2012, Circulation. Cardiovascular interventions.

[13]  M. Buchbinder,et al.  Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[14]  M. Nobuyoshi,et al.  Classification and clinical impact of restenosis after femoropopliteal stenting. , 2012, Journal of the American College of Cardiology.

[15]  J. Laird,et al.  The treatment of femoropopliteal in-stent restenosis: back to the future. , 2012, Journal of the American College of Cardiology.

[16]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[17]  Maurice Buchbinder,et al.  Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the RESILIENT Randomized Trial , 2010, Circulation. Cardiovascular interventions.

[18]  Johannes Lammer,et al.  Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  A. Dyer,et al.  Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. , 2008, Journal of vascular surgery.

[20]  B. Hamm,et al.  Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.

[21]  C. Claussen,et al.  Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. , 2008, The New England journal of medicine.

[22]  L. Norgren,et al.  Inter-society consensus for the management of peripheral arterial disease. , 2007, International angiology : a journal of the International Union of Angiology.

[23]  D. Bloch,et al.  Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  Johannes Lammer,et al.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.

[25]  Martin Schillinger,et al.  Long-Segment SFA Stenting—The Dark Sides: In-Stent Restenosis, Clinical Deterioration, and Stent Fractures , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[26]  Christopher Piorkowski,et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.

[27]  A. Boulton,et al.  Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.

[28]  A. Baumbach,et al.  Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.

[29]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[30]  R. Kester,et al.  Quality of life analysis in patients with lower limb ischaemia: suggestions for European standardisation. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[31]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[32]  John V. White,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.